How does a personalized mRNA vaccine target melanoma recurrence?
Moderna and Merck said on August 19 that their personalized mRNA therapy improved key outcomes in a phase III melanoma trial.
The trial enrolled around 1,100 people whose advanced melanoma had been completely removed and compared intismeran plus pembrolizumab with pembrolizumab alone.[3] The combination met endpoints for recurrence-free survival and distant metastasis-free survival, but detailed phase III efficacy and saf…
The trial enrolled around 1,100 people whose advanced melanoma had been completely removed and compared intismeran plus pembrolizumab with pembrolizumab alone.[3] The combination met endpoints for recurrence-free survival and distant metastasis-free survival, but detailed phase III efficacy and safety results have not yet been released.[4]
Why it matters: This is the first personalized mRNA cancer treatment to report success in a late-stage trial, providing evidence that vaccines tailored to tumour mutations can work at scale.[3] Its clinical value remains uncertain until researchers disclose the magnitude and durability of the benefit, adverse events and longer-term survival outcomes.[3][4]
Key insights: Intismeran is intended to prevent melanoma from returning after treatment, not to prevent someone from developing cancer initially.[3] | A patient's tumour is sequenced to identify mutations and corresponding neoantigens; the customized mRNA then instructs the body to produce selected neoantigens and trains the immune system to recognize the tumour.[3] | Earlier phase IIb results associated the combination with a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death, but those figures are not the still-unreleased phase III effect sizes.[4] | Producing an individualized vaccine can take several months, creating a practical barrier for patients with rapidly progressing advanced cancer.[3]
Cheatsheet facts: What changed: The phase III trial met recurrence-free and distant metastasis-free survival endpoints for intismeran plus pembrolizumab versus pembrolizumab alone.[4] | Why now: Moderna and Merck announced the top-line results after studying around 1,100 patients with surgically removed advanced melanoma.[3][4] | Watch next: Look for the full phase III efficacy and safety data at the planned medical presentation, followed by the companies' submissions to regulatory authorities.[4]
The trial enrolled around 1,100 people whose advanced melanoma had been completely removed and compared intismeran plus pembrolizumab with pembrolizumab alone.[3] The combination met endpoints for recurrence-free survival and distant metastasis-free survival, but detailed phase III efficacy and safety results have not yet been released.[4]
Why it matters: This is the first personalized mRNA cancer treatment to report success in a late-stage trial, providing evidence that vaccines tailored to tumour mutations can work at scale.[3] Its clinical value remains uncertain until researchers disclose the magnitude and durability of the benefit, adverse events and longer-term survival outcomes.[3][4]
Key insights: Intismeran is intended to prevent melanoma from returning after treatment, not to prevent someone from developing cancer initially.[3] | A patient's tumour is sequenced to identify mutations and corresponding neoantigens; the customized mRNA then instructs the body to produce selected neoantigens and trains the immune system to recognize the tumour.[3] | Earlier phase IIb results associated the combination with a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death, but those figures are not the still-unreleased phase III effect sizes.[4] | Producing an individualized vaccine can take several months, creating a practical barrier for patients with rapidly progressing advanced cancer.[3]
Cheatsheet facts: What changed: The phase III trial met recurrence-free and distant metastasis-free survival endpoints for intismeran plus pembrolizumab versus pembrolizumab alone.[4] | Why now: Moderna and Merck announced the top-line results after studying around 1,100 patients with surgically removed advanced melanoma.[3][4] | Watch next: Look for the full phase III efficacy and safety data at the planned medical presentation, followed by the companies' submissions to regulatory authorities.[4]